التفاصيل البيبلوغرافية
| العنوان: |
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. |
| المؤلفون: |
Ross, Jeffrey S., Wang, Kai, Chmielecki, Juliann, Gay, Laurie, Johnson, Adrienne, Chudnovsky, Jacob, Yelensky, Roman, Lipson, Doron, Ali, Siraj M, Elvin, Julia A., Vergilio, Jo‐Anne, Roels, Steven, Miller, Vincent A, Nakamura, Brooke N., Gray, Adam, Wong, Michael K, Stephens, Philip J |
| المصدر: |
International Journal of Cancer; 2/15/2016, Vol. 138 Issue 4, p881-890, 10p, 3 Color Photographs, 1 Diagram, 1 Chart, 1 Graph |
| مستخلص: |
Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the FoundationOneTM or FoundationOne HemeTM comprehensive genomic profiling assays. BRAF fusions involving the intact in-frame BRAF kinase domain were observed in 55 (0.3%) of 20,573 tumors, across 12 distinct tumor types, including 20 novel BRAF fusions. These comprised 29 unique 50 fusion partners, of which 31% (9) were known and 69% (20) were novel. BRAF fusions included 3% (14/531) of melanomas; 2% (15/ 701) of gliomas; 1.0% (3/294) of thyroid cancers; 0.3% (3/1,062) pancreatic carcinomas; 0.2% (8/4,013) nonsmall-cell lung cancers and 0.2% (4/2,154) of colorectal cancers, and were enriched in pilocytic (30%) vs. nonpilocytic gliomas (1%; p < 0.0001), Spitzoid (75%) vs. nonSpitzoid melanomas (1%; p = 0.0001), acinar (67%) vs. nonacinar pancreatic cancers (<1%; p < 0.0001) and papillary (3%) vs. nonpapillary thyroid cancers (0%; p < 0.03). Clinical responses to trametinib and sorafenib are presented. In conclusion, BRAF fusions are rare driver alterations in a wide variety of malignant neoplasms, but enriched in Spitzoid melanoma, pilocytic astrocytomas, pancreatic acinar and papillary thyroid cancers. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Cancer is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
